ketanserin has been researched along with Cancer of Pituitary in 2 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prescott, RW | 1 |
| Ratcliffe, WA | 1 |
| Taylor, PK | 1 |
| Grotewiel, MS | 1 |
| Sanders-Bush, E | 1 |
1 trial available for ketanserin and Cancer of Pituitary
| Article | Year |
|---|---|
Effect of an oral serotonin antagonist, ketanserin, on plasma ACTH concentrations in Nelson's syndrome.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1984 |
1 other study available for ketanserin and Cancer of Pituitary
| Article | Year |
|---|---|
Regulation of serotonin2A receptors in heterologous expression systems.
Topics: 3T3 Cells; Animals; Antiparkinson Agents; Binding, Competitive; Cell Line; Dogs; DOM 2,5-Dimethoxy-4 | 1994 |